Advertisement

The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells

  • Gabriel D. Dakubo
Chapter

Abstract

The altered metabolism of cancer cells was recognized and pioneered by the elegant works of Otto Warburg in the 1920s and popularized in the 1950s. Presently, it is well recognized that over sixty percent of all cancers are glycolytic. The Warburg effect or phenomenon is discussed, and the molecular understanding of some of Warburg’s statements is provided with regard to modern knowledge of carcinogenesis. In addition, molecular explanation of aerobic glycolysis of the cancer cell is detailed. Other metabolic alterations of the cancer cell including glutaminolysis and lipogenesis are discussed. The altered citrate metabolism specifically associated with malignant transformation of peripheral zone prostate epithelial cells, and the potential clinical applications of such metabolic alterations conclude this chapter.

Keywords

Aerobic Glycolysis Fumarate Hydratase Glutamine Metabolism Citrate Transport Protein Citrate Oxidation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Altenberg B, and Greulich KO (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84, 1014–1020.CrossRefPubMedGoogle Scholar
  2. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, and Regev A (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499–507.CrossRefPubMedGoogle Scholar
  3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, and Bartrons R (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120.CrossRefPubMedGoogle Scholar
  4. Billin AN, Eilers AL, Queva C, and Ayer DE (1999). Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors. J Biol Chem 274, 36344–36350CrossRefPubMedGoogle Scholar
  5. Billin AN, Eilers AL, Coulter KL, Logan JS, and Ayer DE (2000). MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network. Mol Cell Biol 20, 8845–8854.CrossRefPubMedGoogle Scholar
  6. Brown GK (2000). Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 23, 237–246.CrossRefPubMedGoogle Scholar
  7. Bustamante E, and Pedersen PL (1977). High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 74, 3735–3739.CrossRefPubMedGoogle Scholar
  8. Cai Z, and Semenza GL (2005). PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 97, 1351–1359.CrossRefPubMedGoogle Scholar
  9. Costello LC, and Franklin RB (2000). The intermediary metabolism of the prostate:a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 59, 269–282.CrossRefPubMedGoogle Scholar
  10. Costello LC, and Franklin RB (2006). The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 5, 17.CrossRefPubMedGoogle Scholar
  11. Costello LC, and Franklin RB (2009). Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem. Prostate Cancer Prostatic Dis 12, 17–24.CrossRefPubMedGoogle Scholar
  12. Costello LC, Franklin RB, and Narayan P (1999). Citrate in the diagnosis of prostate cancer. Prostate 38, 237–245.CrossRefPubMedGoogle Scholar
  13. Costello LC, Feng P, Milon B, Tan M, and Franklin RB (2004). Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 7, 111–117.CrossRefPubMedGoogle Scholar
  14. Costello LC, Franklin RB, Feng P, Tan M, and Bagasra O (2005). Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control 16, 901–915.CrossRefPubMedGoogle Scholar
  15. Crabtree HG (1926). Observations on the carbohydrate metabolism of tumours. Biochem J 23, 536–545.Google Scholar
  16. Dahia PL, Ross KN, Wright ME, et al. (2005). A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1, 72–80.CrossRefPubMedGoogle Scholar
  17. DeBerardinis RJ, Mancuso A, Daikhin E, et al. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104, 19345–19350.CrossRefPubMedGoogle Scholar
  18. Desouki MM, Geradts J, Milon B, Franklin RB, and Costello LC (2007). hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. Mol Cancer 6, 37.CrossRefPubMedGoogle Scholar
  19. Feng P, Li T, Guan Z, Franklin RB, and Costello LC (2008). The involvement of Bax in zinc-induced mitochondrial apoptogenesis in malignant prostate cells. Mol Cancer 7, 25.CrossRefPubMedGoogle Scholar
  20. Franklin RB, and Costello LC (2007). Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 463, 211–217.CrossRefPubMedGoogle Scholar
  21. Franklin RB, and Costello LC (2009). The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 106, 750–757.CrossRefPubMedGoogle Scholar
  22. Fukuda R, Zhang H, Kim JW, et al. (2007). HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111–122.CrossRefPubMedGoogle Scholar
  23. Gallus S, Foschi R, Negri E, et al. (2007). Dietary zinc and prostate cancer risk: a case-control study from Italy. Eur Urol 52, 1052–1056.CrossRefPubMedGoogle Scholar
  24. Gonzalez A, Peters U, Lampe JW, and White E (2009). Zinc intake from supplements and diet and prostate cancer. Nutr Cancer 61, 206–215.CrossRefPubMedGoogle Scholar
  25. Guzy RD, Hoyos B, Robin E, et al. (2005). Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1, 401–408.CrossRefPubMedGoogle Scholar
  26. Guzy RD, Sharma B, Bell E, Chandel NS, and Schumacker PT (2008). Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28, 718–731.CrossRefPubMedGoogle Scholar
  27. Harman D (1956). Aging: a theory based on free radical and radiation chemistry. J Gerontol 11, 298–300.PubMedGoogle Scholar
  28. Hausenloy DJ, Tsang A, Mocanu MM, and Yellon DM (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288, H971–976.CrossRefGoogle Scholar
  29. Heinz A, Sachs G, and Schafer JA (1981). Evidence for activation of an active electrogenic proton pump in Ehrlich ascites tumor cells during glycolysis. J Membr Biol 61, 143–153.CrossRefPubMedGoogle Scholar
  30. Hu CJ, Sataur A, Wang L, Chen H, and Simon MC (2007). The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 18, 4528–4542.CrossRefPubMedGoogle Scholar
  31. Jiang BH, Agani F, Passaniti A, and Semenza GL (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57, 5328–5335.PubMedGoogle Scholar
  32. Jung JA, Coakley FV, Vigneron DB, et al. (2004). Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 233, 701–708.CrossRefPubMedGoogle Scholar
  33. Kaelin WG, Jr. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2, 673–682.CrossRefPubMedGoogle Scholar
  34. Kaelin WG (2005). The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 70, 159–166.CrossRefPubMedGoogle Scholar
  35. Kim JW, and Dang CV (2005). Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30, 142–150.CrossRefPubMedGoogle Scholar
  36. Klimova T, and Chandel NS (2008). Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 15, 660–666.CrossRefPubMedGoogle Scholar
  37. Kondoh H, Lleonart ME, Bernard D, and Gil J (2007). Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol Histopathol 22, 85–90.PubMedGoogle Scholar
  38. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, and Harris AL (2005). Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 7, 1–6.CrossRefPubMedGoogle Scholar
  39. Laughner E, Taghavi P, Chiles K, Mahon PC, and Semenza GL (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21, 3995–4004.CrossRefPubMedGoogle Scholar
  40. Li F, Wang Y, Zeller KI, et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25, 6225–6234.CrossRefPubMedGoogle Scholar
  41. Linehan WM, Walther MM, and Zbar B (2003). The genetic basis of cancer of the kidney. J Urol 170, 2163–2172.CrossRefPubMedGoogle Scholar
  42. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, et al. (2007). Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 67, 9013–9017.CrossRefPubMedGoogle Scholar
  43. Lu H, Dalgard CL, Mohyeldin A, et al. (2005). Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280, 41928–41939.CrossRefPubMedGoogle Scholar
  44. Mathupala SP, Rempel A, and Pedersen PL (1997). Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29, 339–343.CrossRefPubMedGoogle Scholar
  45. Mathupala SP, Ko YH, and Pedersen PL (2006). Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25, 4777–4786.CrossRefPubMedGoogle Scholar
  46. Matoba S, Kang JG, Patino WD, et al. (2006). p53 regulates mitochondrial respiration. Science 312, 1650–1653.CrossRefPubMedGoogle Scholar
  47. Mayer D, Klimek F, Rempel A, and Bannasch P (1997). Hexokinase expression in liver preneoplasia and neoplasia. Biochem Soc Trans 25, 122–127.PubMedGoogle Scholar
  48. Maynard MA, and Ohh M (2004). Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24, 1–13.CrossRefPubMedGoogle Scholar
  49. McFate T, Mohyeldin A, Lu H, et al. (2008). Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283, 22700–22708.CrossRefPubMedGoogle Scholar
  50. Miquel J, Binnard R, and Fleming JE (1983). Role of metabolic rate and DNA-repair in Drosophila aging: implications for the mitochondrial mutation theory of aging. Exp Gerontol 18, 167–171.CrossRefPubMedGoogle Scholar
  51. Mocanu MM, Bell RM, and Yellon DM (2002). PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34, 661–668.CrossRefPubMedGoogle Scholar
  52. Moro L, Arbini AA, Yao JL, et al. (2008). Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ.Google Scholar
  53. Murry CE, Jennings RB, and Reimer KA (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124–1136.PubMedGoogle Scholar
  54. Ogawa Y, Kobayashi T, Nishioka A, et al. (2003). Radiation-induced reactive oxygen species formation prior to oxidative DNA damage in human peripheral T cells. Int J Mol Med 11, 149–152.PubMedGoogle Scholar
  55. Osthus RC, Shim H, Kim S, et al. (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275, 21797–21800.CrossRefPubMedGoogle Scholar
  56. Papandreou I, Cairns RA, Fontana L, Lim AL, and Denko NC (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3, 187–197.CrossRefPubMedGoogle Scholar
  57. Patel MS, and Korotchkina LG (2001). Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med 33, 191–197.PubMedGoogle Scholar
  58. Pedersen PL (2007). Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39, 211–222.CrossRefPubMedGoogle Scholar
  59. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, and Ko YH (2002). Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555, 14–20.CrossRefPubMedGoogle Scholar
  60. Plas DR, and Thompson CB (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435–7442.CrossRefPubMedGoogle Scholar
  61. Pollard P, Wortham N, Barclay E, et al. (2005a). Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 205, 41–49.CrossRefPubMedGoogle Scholar
  62. Pollard PJ, Briere JJ, Alam NA, et al. (2005b). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231–2239.CrossRefPubMedGoogle Scholar
  63. Pomare EW, Branch WJ, and Cummings JH (1985). Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 75, 1448–1454.CrossRefPubMedGoogle Scholar
  64. Prahl S, Kueper T, Biernoth T, et al. (2008). Aging skin is functionally anaerobic: importance of coenzyme Q10 for anti aging skin care. Biofactors 32, 245–255.CrossRefPubMedGoogle Scholar
  65. Prando A, Kurhanewicz J, Borges AP, Oliveira EM, Jr., and Figueiredo E (2005). Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236, 903–910.CrossRefPubMedGoogle Scholar
  66. Rempel A, Bannasch P, and Mayer D (1994). Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219, 660–668.PubMedGoogle Scholar
  67. Rodriguez-Enriquez S, Juarez O, Rodriguez-Zavala JS, and Moreno-Sanchez R (2001). Multisite control of the Crabtree effect in ascites hepatoma cells. Eur J Biochem 268, 2512–2519.CrossRefPubMedGoogle Scholar
  68. Sans CL, Satterwhite DJ, Stoltzman CA, Breen KT, and Ayer DE (2006). MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol 26, 4863–4871.CrossRefPubMedGoogle Scholar
  69. Schofield CJ, and Ratcliffe PJ (2005). Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 338, 617–626.CrossRefPubMedGoogle Scholar
  70. Semenza GL, and Wang GL (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447–5454.PubMedGoogle Scholar
  71. Sheta EA, Trout H, Gildea JJ, Harding MA, and Theodorescu D (2001). Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 20, 7624–7634.CrossRefPubMedGoogle Scholar
  72. Simon MC (2006). Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Adv Exp Med Biol 588, 165–170.CrossRefPubMedGoogle Scholar
  73. Singh KK, Desouki MM, Franklin RB, and Costello LC (2006). Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 5, 14.CrossRefPubMedGoogle Scholar
  74. Sussman I, Erecinska M, and Wilson DF (1980). Regulation of cellular energy metabolism: the Crabtree effect. Biochim Biophys Acta 591, 209–223.CrossRefPubMedGoogle Scholar
  75. Tian H, McKnight SL, and Russell DW (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11, 72–82.CrossRefPubMedGoogle Scholar
  76. Tong H, Chen W, Steenbergen C, and Murphy E (2000). Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87, 309–315.PubMedGoogle Scholar
  77. Uddin S, Siraj AK, Al-Rasheed M, et al. (2008). Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 93, 4088–4097.CrossRefPubMedGoogle Scholar
  78. Umbehr M, Bachmann LM, Held U, et al. (2008). Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol.Google Scholar
  79. Vanharanta S, Pollard PJ, Lehtonen HJ, et al. (2006). Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet 15, 97–103.CrossRefPubMedGoogle Scholar
  80. Warburg O (1956). On the origin of cancer cells. Science 123, 309–314.CrossRefPubMedGoogle Scholar
  81. Wilson JE (1997). An introduction to the isoenzymes of mammalian hexokinase types I-III. Biochem Soc Trans 25, 103–107.PubMedGoogle Scholar
  82. Wilson JE (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206, 2049–2057.CrossRefPubMedGoogle Scholar
  83. Wise DR, DeBerardinis RJ, Mancuso A, et al. (2008). Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105, 18782–18787.CrossRefPubMedGoogle Scholar
  84. Wojtczak L (1996). The Crabtree effect: a new look at the old problem. Acta Biochim Pol 43, 361–368.PubMedGoogle Scholar
  85. Yang X, Borg LA, and Eriksson UJ (1997). Altered metabolism and superoxide generation in neural tissue of rat embryos exposed to high glucose. Am J Physiol 272, E173–180.Google Scholar
  86. Zakian KL, Sircar K, Hricak H, et al. (2005). Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234, 804–814.CrossRefPubMedGoogle Scholar
  87. Zhang H, Gao P, Fukuda R, et al. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407–420.CrossRefPubMedGoogle Scholar
  88. Zhao ZQ, Corvera JS, Halkos ME, et al. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285, H579–588.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Genesis Genomics, Inc.Thunder BayCanada

Personalised recommendations